# Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.

> **NCT05864014** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 213 (actual)

## Conditions studied

- Chemotherapy-Induced Thrombocytopenia

## Interventions

- **DRUG:** Hetrombopag
- **DRUG:** Hetrombopag plus Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05864014
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-04-25
- **Primary completion:** 2025-03-03
- **Final completion:** 2025-09
- **Target enrollment:** 213 (ACTUAL)
- **Last updated:** 2025-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05864014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05864014, "Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05864014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*